Form 4: Rhythm Pharma Grants EVP 23,350 Restricted Stock Units

Rhythm Pharmaceuticals, Inc. disclosed an equity grant of 23,350 restricted stock units to EVP Yann Mazabraud, vesting over four years.

Summary

• Yann Mazabraud, Executive Vice President and Head of International at Rhythm Pharmaceuticals, Inc. (RYTM), was granted 23,350 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the company's common stock.
• The RSUs were granted on February 11, 2026, with a transaction price of $0.
• The vesting schedule for these RSUs is 25% on March 1, 2027, and 25% on February 1st of 2028, 2029, and 2030.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive incentive practices and a commitment to long-term executive retention, which is generally favorable for stability and strategic execution.

Positives

• The grant of Restricted Stock Units (RSUs) to a key executive, Yann Mazabraud, aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention and sustained performance.

Negatives

• Future dilution risk for existing shareholders, although minor for this specific grant, as RSUs convert to common stock upon vesting.

Risks

• Future dilution of existing shareholders upon the vesting and conversion of the 23,350 Restricted Stock Units into common stock.
• The value of the granted RSUs is contingent on the future performance of Rhythm Pharmaceuticals' stock price.

Future Outlook

The Restricted Stock Units are scheduled to vest in four annual installments, beginning March 1, 2027, and concluding February 1, 2030, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units, is a standard practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key executives. This grant to a Head of International suggests a focus on global market expansion and performance, aligning executive incentives with the company's strategic growth objectives.

Comparison to Industry Standards

• The grant of 23,350 RSUs to an EVP is within the typical range for executive equity compensation in mid-cap biotech companies, comparable to grants observed at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals for similar roles, though the specific value depends on RYTM's market capitalization and compensation philosophy.
• A four-year vesting schedule with annual installments is a common industry standard, designed to promote long-term commitment and performance, similar to practices seen at companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but also increased alignment of executive interests with long-term stock performance.
• Employees: May signal a stable compensation strategy and commitment to executive talent.

Next Steps

• The Restricted Stock Units will vest in four equal annual installments on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a senior executive, which is a standard practice for public companies to incentivize and retain talent. While it aligns executive interests with long-term shareholder value, it does not present new information that would fundamentally alter the investment thesis for Rhythm Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate as this event alone is unlikely to drive significant stock price movement or warrant a change in existing positions.

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Restricted Stock Units, RSU, Equity Compensation, Yann Mazabraud, Executive Compensation, Insider Transaction, Stock Grant